# EDGAR Filing Document

**Accession Number:** 0001419351
**File Stem:** 0001387131-23-000335
**Filing Date:** 2023-1
**Character Count:** 13333
**Document Hash:** 49658376732ab89cade2c6e16721a11b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001387131-23-000335.hdr.sgml**: 20230113

**ACCESSION NUMBER**: 0001387131-23-000335

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221223

**FILED AS OF DATE**: 20230113

**DATE AS OF CHANGE**: 20230113

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Mamoura Diversified Global Holding PJSC
- **CENTRAL INDEX KEY:** 0001419351
- **STATE OF INCORPORATION:** C0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40323
- **FILM NUMBER:** 23529003

**BUSINESS ADDRESS:**
- **STREET 1:** P. O. BOX 45005
- **CITY:** ABU DHABI
- **STATE:** C0
- **ZIP:** UAE
- **BUSINESS PHONE:** 971.2.616.0099

**MAIL ADDRESS:**
- **STREET 1:** P. O. BOX 45005
- **CITY:** ABU DHABI
- **STATE:** C0
- **ZIP:** UAE

**FORMER NAME:**
- **FORMER CONFORMED NAME:** MUBADALA DEVELOPMENT CO PJSC
- **DATE OF NAME CHANGE:** 20071126
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Mubadala Investment Co PJSC
- **CENTRAL INDEX KEY:** 0001704268
- **STATE OF INCORPORATION:** C0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40323
- **FILM NUMBER:** 23529004

**BUSINESS ADDRESS:**
- **STREET 1:** P.O. BOX 45005
- **CITY:** ABU DHABI
- **STATE:** C0
- **ZIP:** 00000
- **BUSINESS PHONE:** 971-2413-0000

**MAIL ADDRESS:**
- **STREET 1:** P.O. BOX 45005
- **CITY:** ABU DHABI
- **STATE:** C0
- **ZIP:** 00000
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RECURSION PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001601830
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 464099738
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 41S RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101
- **BUSINESS PHONE:** (385) 269-0203

**MAIL ADDRESS:**
- **STREET 1:** 41S RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Recursion Pharmaceuticals, LLC
- **DATE OF NAME CHANGE:** 20140305

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Mubadala Investment Co PJSC<br><sub>(Last) (First) (Middle)</sub><br>P.O. BOX 45005<br><sub>(Street)</sub><br>ABU DHABI, C0 00000<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-12-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>RECURSION PHARMACEUTICALS, INC. [ RXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Mamoura Diversified Global Holding PJSC<br><sub>(Last) (First) (Middle)</sub><br>P. O. BOX 45005<br><sub>(Street)</sub><br>ABU DHABI, C0 UAE<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-12-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>RECURSION PHARMACEUTICALS, INC. [ RXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Common Stock | 2022-12-23<sup>(1)</sup> |  | P |  | 100378 | A | 7.5158<sup>(2)</sup> | 11392315 | I | See Explanation of Responses<sup>(13)(15)(16)</sup> |
| Class A Common Stock | 2022-12-27<sup>(1)</sup> |  | P |  | 145652 | A | 7.2392<sup>(3)</sup> | 11537967 | I | See Explanation of Responses<sup>(13)(15)(16)</sup> |
| Class A Common Stock | 2022-12-28<sup>(1)</sup> |  | P |  | 71299 | A | 7.1796<sup>(4)</sup> | 11609266 | I | See Explanation of Responses<sup>(13)(15)(16)</sup> |
| Class A Common Stock | 2022-12-29<sup>(1)</sup> |  | P |  | 84622 | A | 7.7140<sup>(5)</sup> | 11693888 | I | See Explanation of Responses<sup>(13)(15)(16)</sup> |
| Class A Common Stock | 2022-12-30<sup>(1)</sup> |  | P |  | 99754 | A | 7.5548<sup>(6)</sup> | 11793642 | I | See Explanation of Responses<sup>(13)(15)(16)</sup> |
| Class A Common Stock | 2023-01-03<sup>(1)</sup> |  | P |  | 141646 | A | 7.5047<sup>(7)</sup> | 11935288 | I | See Explanation of Responses<sup>(13)(15)(16)</sup> |
| Class A Common Stock | 2023-01-04<sup>(1)</sup> |  | P |  | 91892 | A | 7.8013<sup>(8)</sup> | 12027180 | I | See Explanation of Responses<sup>(13)(15)(16)</sup> |
| Class A Common Stock | 2023-01-05<sup>(1)</sup> |  | P |  | 80035 | A | 7.3787<sup>(9)</sup> | 12107215 | I | See Explanation of Responses<sup>(13)(15)(16)</sup> |
| Class A Common Stock | 2023-01-06<sup>(1)</sup> |  | P |  | 68953 | A | 7.4052<sup>(10)</sup> | 12176168 | I | See Explanation of Responses<sup>(13)(15)(16)</sup> |
| Class A Common Stock | 2023-01-09<sup>(1)</sup> |  | P |  | 76046 | A | 7.6380<sup>(11)</sup> | 12252214 | I | See Explanation of Responses<sup>(13)(15)(16)</sup> |
| Class A Common Stock | 2023-01-10<sup>(1)</sup> |  | P |  | 69518 | A | 7.7224<sup>(12)</sup> | 12321732 | I | See Explanation of Responses<sup>(13)(15)(16)</sup> |
| Class A Common Stock |  |  |  |  |  |  |  | 7062869 | I | See Explanation of Responses<sup>(14)(15)(16)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) This is an inadvertent late filing due to an administrative error.

(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.70, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (12) to this Form4.

(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.61, inclusive.

(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.07 to $7.32, inclusive.

(5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.25 to $7.91, inclusive.

(6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.72, inclusive.

(7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.37 to $7.83, inclusive.

(8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $7.88, inclusive.

(9) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.75, inclusive.

(10) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.10 to $8.00, inclusive.

(11) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.43 to $8.00, inclusive.

(12) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $8.00, inclusive.

(13) Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi.

(14) MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.

(15) Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

(16) Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

**Remarks:**
17. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.

**Signature:** /s/ Samer Halawa, Chief Legal Officer, Mubadala Investment Company PJSC (17)  
**Date:** 2023-01-13

**Signature:** /s/ Samer Halawa, Chief Legal Officer, Mamoura Diversified Global Holdings PJSC (17)  
**Date:** 2023-01-13

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**